As the @EHA_Hematology Congress (#EHA2026) kicks off, hear from Steve Tuplin, Haematology Franchise Head at Roche, on our commitment to exploring combination approaches that advance B-cell malignancy outcomes. 👇

#MEDIA – We are pleased that the US FDA has accepted the New Drug Application for our investigational medicine in ER-positive early-stage #BreastCancer in the adjuvant setting spkl.io/6010764LG $ROG $RHHBY

Mass spectrometry is transforming diagnostics, but simply having the tech isn't enough. The real breakthrough comes from seamlessly integrating it into the lab's entire workflow. Hear from Roche’s Benjamin Lilienfield about the value of integration to healthcare labs. go.roche.com/bjms #RocheMassSpec

#MEDIA - Chronic liver disease causes more than two million deaths worldwide every year, despite 90% of cases being preventable. To help address this, Roche is launching a comprehensive Liver Disease Panel, featuring certified algorithms to improve early detection. roche.com/media/releases #DigitalHealth #EarlyDetection #CLD

Big News from the World Health Assembly! 🌍 Roche and the @MedsPatentPool sign voluntary license agreement to expand global access to innovative antiviral medicine in low-and-middle income countries and strengthen global health resilience against influenza 🏥 For more information, visit: spkl.io/6018Ah9SC #GlobalHealth #AccesstoMedicines #HealthSecurity #GlobalHealthSecurity #PandemicPreparedness #VoluntaryLicensing #WHA79

In critical care, every second counts. And now scientists can generate answers – in record time. Hear about how sequencing by expansion (SBX) technology is evolving genomics: youtube.com/watch?v=O2IANAoP… (The SBX technology is in development and not commercially available. The content of this material reflects current study results and/or design goals.) #Genomics #HumanGenetics #RocheSBX #Innovation #NGS

Alzheimer's changes can start decades before symptoms, a critical window for intervention. Roche is tackling this with blood technologies for earlier detection, helping individuals plan care and slow disease progression. go.roche.com/xptauorg #Innovation #Healthcare #Technology #Alzheimers #Neuroscience

#MEDIA – We are pleased to share our data from nine approved and investigational medicines at #ASCO26, with the potential to advance the treatment of #breast, #lung, #bladder, #colon cancers and #lymphoma. spkl.io/6015Ah82x $ROP $RHHBY

#MEDIA - New data show the Elecsys pTau217 blood test achieves accuracy comparable to PET for detecting Alzheimer's amyloid pathology, enabling scalable testing from a simple blood draw in routine care settings. roche.com/media/releases #Healthcare #Alzheimers #Neuroscience $ROG $RHHBY

This #WorldLupusDay, we’re raising awareness of the real-world impact of lupus, and the realities people face everyday. Around 3.4 million people worldwide are living with #SystemicLupusErythematosus (SLE). Up to 1 in 3 adults with SLE have #LupusNephritis at diagnosis, and up to 50% may develop it within five years. Lupus can affect multiple organs, including the kidneys, and it can take 2-6 years to receive an accurate diagnosis - during which time disease flares may lead to irreversible organ damage and reduced quality of life. Click here to learn more about SLE and lupus nephritis! #LupusAwarenessMonth #LivingWithLupus #SystemicLupusErythematosus #SLE #LupusNephritis

How could sequencing by expansion (SBX) technology could shape cancer research? Find out more: youtube.com/watch?v=CYvbm1Td… (The SBX technology is in development and not commercially available. The content of this material reflects current study results and/or design goals.) #Genomics #HumanGenetics #RocheSBX #Innovation #NGS

#MEDIA - At #ARVO2026, we’re pleased to share promising data showing progress in preserving vision and managing complex retinal conditions. roche.com/media

We’re proud to announce our continued collaboration with the @wfhemophilia, through their Humanitarian Aid Program, working together to expand access to care for people with #haemophilia in locations where there is little to no access to treatment. Read more via their website: spkl.io/6015AfRCd #BleedingDisorders #PublicHealth #WFHCongress2026

Roche reports strong sales growth of 6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc. For more details, click here ➡️ spkl.io/6011AfHJR $ROG $RHHBY #FinancialResults

#MEDIA - We’re pleased to share detailed, late-breaking results at #AANAM from two positive Phase III studies of our investigational oral, brain-penetrant medicine in relapsing multiple sclerosis. roche.com/media $RHHBY $ROP

#MEDIA - At #AANAM , we’re pleased to share new positive Phase III data in myelin oligodendrocyte glycoprotein antibody-associated disease (#MOGAD), a disease for which there are no approved treatments. roche.com/media $RHHBY $ROP

#MEDIA – We are pleased to announce that the US FDA has accepted Roche’s New Drug Application in #SystemicLupusErythematos. This important step moves us closer to providing a first-of-its-kind targeted treatment for people whose lives are significantly impacted by this debilitating autoimmune disease. roche.com/media/releases $ROG $RHHBY

Sequencing by expansion (SBX) is being designed to transform next-gen sequencing (NGS). Scientists will choose the best tool for their needs, adjust read lengths on one system, and handle small or large batches with ease. Discover how SBX is poised to revolutionize disease research. go.roche.com/xsbxflx #NGS #Genomics #Innovation #MakeSpaceWithSBX #RocheSBX

Diagnostics are the "intelligence" of health security. Roche is proud to join the Global One Health Diagnostics Access Compact to help expand access to reliable testing and build a more resilient tomorrow. Together, we can make the shift towards proactive care. #OneHealth #AMR

New CE‑marked blood test complements MRI with a simple, minimally invasive option for more regular monitoring of neuroinflammation‑related activity in adults diagnosed with RRMS, supporting earlier and better‑informed clinical management. roche.com/media $RHHBY $ROG